Igyxos is a French biotechnology company dedicated to addressing the growing global need for improved infertility solutions through novel therapeutics that make treatment more effective and efficient for men and women. Igyxos’ lead asset is IGX12, a first-in-class humanized monoclonal antibody which is Phase 2 ready.